What do you guys think MDMAI Would be like?
Very similar. If I'm not mistaken, MDMAI is even a bit more selective for 5ht release, sans 5ht2a agonism or other monoaminergic release. But MDAI already holds such properties.
im really curious about how this differs metabolically and pharmacologically from MBDB. would MBDB be metabolized into alpha-ethyl-dopamine and has that been studied? from what i gather this stuff seem quite superior to MBDB in both toxicity and potency, if anyone has tried both (unlikely i know) i would LOVE to hear a comparison of the subjective effects.
Good questions. I'm not knowledgeable enough about this type of thing, but doesn't mdma metabolize to alpha-methyl-dopamine, a dopaminergic antagonist (yuck!!)? Would a-e-da exert similar action? I know that a-m-norepi' from bk-mdma isn't as much of a problem (read: dysphoric after-effect), as I'd guess that a-e-norepi' would be similar.
vs. MBDB: well, the latter releases norepi' in substantial amounts too, so we'd expect it to be more stimulating (but not in that focused, DA way)...but a lot of reports show it to be quite sedating, so I dunno.
re: neurotoxicity: through which mechanism is MBDB neurotoxic? Minor DA release? Toxic metabolites due to the methylene-dioxy ring structure? Are all 3,4-methylenedioxy substituted agents neurotoxic then? If it's the latter, then we'd want a 5ht releaser w/o that substitution. Link to the study?
...
Nichols has a good paper comparing MDAI to a few things:
J. Med. Chem. 1993,36,3700-3706
Synthesis and Pharmacological Examination of Benzofuran, Indan, and Tetralin
Analogues of 3,4-( Methy1enedioxy)amphetamine
Aaron P. Monte, Danuta Marona-Lewicka, Nicholas V. Cozzi, and David E. Nichols'
Departments of Medicinal Chemistry and Pharmacognosy and Pharmacology and Toxicology, School of Pharmacy and
Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907
I'd attach it, but it's obviously too large.